Can nitric oxide donors increase uterine blood flow to improve endometrial receptivity and pregnancy outcome in patients with unexplained recurrent abortion?

Completed

• Conditions: unexplained recurrent abortion; decrease uterine artery and sub-endometrial blood flow; Reproductive Health and Childbirth - Abortion

• Registration Number: ACTRN12614000069651
• Lead Sponsor: Benha university hospital

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2014-01-21
• Last Update Posted: 13 January 2020

Recruitment & Eligibility

• Status: Completed
• Sex: Female
• Target Recruitment: 60

Inclusion Criteria

The control group included primipara who had a normal vaginal delivery and no history of abortion. The unexplained recurrent abortion group (URA) group had the following inclusion criteria: 1- Nullipara. 2- History of two or more successive URA. Diagnosis of URA entails1 presence of a normal uterine cavity by hysterography, no luteal phase defect (progesterone level greater than 10 ng / ml), normal thyroid function tests (TSH, T3 and T4), normal levels of lupus anticoagulant measured by the activated partial thromboplastin time (32 - 43 seconds), normal levels of anticardiolipin IgG (less than 20 GPL) and IgM (less than 15 MPL) antibodies measured by ELISA and normal karyotyping (done for 10 cases with more than three successive abortions). Patients treated with vasodilators were also excluded.

Exclusion Criteria

Exclusion criteria in the control group includes: Women using hormonal or intrauterine device contraception or treated with vasodilators.

Exclusion criteria in the abortion group include: patients treated with vasodilators.

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Doppler ultrasound measurement of uterine artery resistance and pulsation indices[Two hours after vaginal administration of 20 mg isosorbid mononitrate];Three dimensions power Doppler ultrasound and the histogram and VOCAL facility for measuring the sub-endometrial vascular, flow and vascular-flow indices[Two hours after vaginal administration of 20 mg isosorbid mononitrate]

Secondary Outcome Measures

Name	Time	Method
il[Nil]